EVALUATION OF METHYLATION PROFILES OF AN
EPIDERMAL GROWTH FACTOR RECEPTOR GENE
IN A HEAD AND NECK SQUAMOUS CELL
CARCINOMA PATIENT GROUP
Mutlu M, Mutlu P, Azarkan S, Bayır O, Ocal B, Saylam G, Korkmaz MH
*Corresponding Author: Associate Professor Murad Mutlu, M.D., Department of Otorhinolaringology,
Health Sciences University, Ministry of Health, Dışkapı Yildirim Beyazit Training and Research Hopsital,
Sehit Ömer Halisdemir Street, No. 20, 06110, Dışkapı, Ankara, Turkey. Tel.: +90-312-516-2000.
Fax: +90-312-318-6690. E-mail: muradmutlu78@yahoo.com
page: 65
|
|
REFERENCES
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer
statistics. CA Cancer J Clin. 2005; 55(2): 74-108.
2. Boonkitticharoen V, Kulapaditharom B, Leopairut J,
Kraiphibul P, Larbcharoensub N, Cheewaruangroj W, et
al. Vascular endothelial growth factor a and proliferation
marker in prediction of lymph node metastasis in oral
and pharyngeal squamous cell carcinoma. Arch Otolaryngol
Head Neck Surg. 2008; 134(12): 1305-1311.
3. Eleftheriadou A, Chalastras T, Ferekidou E, Yio-takis
I, Kyriou L, Tzagarakis M, et al. Association between
squamous cell carcinoma of the head and neck and serum
folate and homocysteine. Anticancer Res. 2006;
26(3B): 2345-2348.
4. Lo AK, Lo KW, Tsao SW, Wong HL, Hui JW, To
KF, et al. Epstein-Barr virus infection alters cellular
signal cascades in human nasopharyngeal epithelial
cells. Neoplasia. 2006; 8(3): 173-180.
5. Hennessey PT, Westra WH, Califano JA. Human
papillomavirus and head and neck squamous cell
carcinoma: recent evidence and clinical implications.
J Dent Res. 2009; 88(4): 300-306.
6. Weber BL. Cancer genomics. Cancer Cell. 2002; 1(1):
37-47.
7. Ha PK, Chang SS, Glazer CA, Califano JA, Sidransky
D. Molecular techniques and genetic alterations
in head and neck cancer. Oral Oncol. 2009; 45(4-5):
335-339.
8. Cassidy LD, Venkitaraman AR. Genome instability
mechanisms and the structure of cancer genomes.
Curr Opin Genet Dev. 2012; 22(1): 10-13.
9. Viet CT, Schmidt BL. Understanding oral cancer in
the genome era. Head Neck. 2010; 32(9): 1246-1268.
10. Agrawal N, Frederick MJ, Pickering CR, Bettegowda
C, Chang K, Li RJ, et al. Exome sequencing
of head and neck squamous cell carcinoma reveals
inactivating mutations in NOTCH1. Science. 2011;
333(6046): 1154-1157.
11. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis
K, Sivachenko A, et al. The mutational landscape
of head and neck squamous cell carcinoma. Science.
2011; 333(6046): 1157-1160.
12. Chung CH, Ely K, McGavran L, Varella-Garcia M,
Parker J, Parker N, et al. Increased epidermal growth
factor receptor gene copy number is associated with
poor prognosis in head and neck squamous cell carcinomas.
J Clin Oncol. 2006; 24(25): 4170-4176.
13. Hynes NE, Lane HA. ERBB receptors and cancer: the
complexity of targeted inhibitors. Nat Rev Cancer.
2005; 5(5): 341-354.
14. Leemans CR, Braakhuis BJ, Brakenhoff RH. The
molecular biology of head and neck cancer. Nat Rev
Cancer. 2010; 11(1): 9-22.
15. Kanai Y, Hirohashi S. Alterations of DNA methylation
associated with abnormalities of DNA methyltransferases
in human cancers during transition from precancerous
to malignant state. Carcinogenesis. 2007;
28(12): 2434-2442.
16. Jones PA, Baylin SB. The fundamental role of epigenetic
events in cancer. Nat Rev Genet. 2002; 3(6):
415-428.
17. Ushijima T. Detection and interpretation of altered
methylation patterns in cancer cells. Nat Rev Cancer.
2005; 5(3): 223-231.
18. Baylin SB, Ohm JE. Epigenetic gene silencing in
cancer – a mechanism for early oncogenic pathway
addiction? Nat Rev Cancer. 2006; 6(2): 107-116.
19. Lee S, Kim WH, Jung HY, Yang MH, Kang GH.
Aberrant CpG island methylation of multiple genes
in intrahepatic cholangiocarcinoma. Am J Pathol.
2002; 161(3): 1015-1022.
20. Hasegawa M, Nelson HH, Peters E, Ringstrom E,
Posner M, Kelsey KT. Patterns of gene promoter
methylation in squamous cell cancer of the head and
neck. Oncogene. 2002; 21(27): 4231-4236.
21. Loyo M, Brait M, Kim MS, Ostrow KL, Jie CC,
Chuang AY, et al. A survey of methylated candidate
tumor suppressor genes in nasopharyngeal carcinoma.
Int J Cancer. 2011; 128(6): 1393-1403.
22. Dikshit RP, Gillio-Tos A, Brennan P, De Marco L,
Fiano V, Martinez-Peñuela JM, et al. Hypermethylation,
risk factors, clinical characteristics, and survival
in 235 patients with laryngeal and hypopharyngeal
cancers. Cancer. 2007; 110(8): 1745-1751.
23. Poage GM, Christensen BC, Houseman EA, Mc-
Clean MD, Wiencke JK, Posner MR, et al. Genetic
and epigenetic somatic alterations in head and neck
squamous cell carcinomas are globally coordinated
but not locally targeted. PLoS One. 2010; 5(3): e9651.
24. Sanchez-Cespedes M, Esteller M, Wu L, Yoo GH,
Koch WM, Jen J, et al. Gene promoter hypermethylation
in tumors and serum of head and neck cancer
patients. Cancer Res. 2000; 60(4): 892-895.
25. Ogi K, Toyota M, Ohe-Toyota M, Tanaka N, Noguchi
M, Sonoda T, et al. Aberrant methylation of multiple
genes and clinicopathological features in oral squamous
cell carcinoma. Clin Cancer Res. 2002; 8(10):
3164-3171.
26. Saloura V, Vougiouklakis T, Zewde M, Deng X,
Kiyotani K, Park J-H, et al. WHSC1L1-mediated
EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and
neck cancer. Sci Rep. 2017; 7: 40664.
27. Liao H-W, Hsu J-M, Xia W, Wang H-L, Wang Y-N,
Chang W-C, et al. PRMT1-mediated methylation of
the EGF receptor regulates signaling and cetuximab
response. J Clin Invest. 2015; 125(12): 4529-4543.
28. Stein RA. Epigenetics-the link between infectious
diseases and cancer. JAMA. 2011; 305(14): 1484-
1485.
29. Nagothu KK, Rishi AK, Jaszewski R, Kucuk O,
Majumdar APN. Folic acid- mediated inhibition of
serum-induced activation of EGFR promoter in colon
cancer cells. Am J Physiol Gastrointest Liver Physiol.
2004; 287(3): G541-G546.
30. Langevin SM, Koestler DC, Christensen BC, Butler
RA, Wiencke JK, Nelson HH, et al. Peripheral blood
DNA methylation profiles are indicative of head and
neck squamous cell carcinoma: An epigenome-wide
association study. Epigenetics. 2012; 7(3): 291-299.
31. Rosas SL, Koch W, Costa Carvalho MG, Wu L, Califano
J, Westra W, et al. Promoter hypermethylation
patterns of p16 O-6-methylguanine-DNA methyltransferase,
and death-associated protein kinase in
tumors and saliva of head and neck cancer patients.
Cancer Res. 2001; 61(3): 939-942.
32. Nagase H, Ghosh S. Epigenetics: differential DNA
methylation in mammalian somatic tissues. FEBS J.
2008; 275(8): 1617-1623.
33. Costello JF, Frushwald MC, Smiraglia DJ, Rush LJ,
Robertson GP, Gao X, et al. Aberrant CpG-island
methylation has non-random and tumor-type-specific
patterns. Nat Genet. 2000; 24(2): 132-138.
34. Goldenberg D, Harden S, Masayesva BG, Ha P, Benoit
N, Westra WH, et al. Intraoperative molecular
margin analysis in head and neck cancer. Arch Otolaryngol
Head Neck Surg. 2004; 130(1): 39-44.
35. Zvonko M, Supić G, Branković-Magić M, Jović
N. DNA methylation in the pathogenesis of head
and neck cancer. In: Dricu A, editor. Methylation
– From DNA, RNA and Histones to Diseases and
Treatment. London, UK: InTech. 2012: 185-216. doi:
10.5772/51169.
36. Arantes LMRB, de Carvalho AC, Melendez ME,
Carvalho AL, Goloni-Bertollo EM. Methylation as
a biomarker for head and neck cancer. Oral Oncol.
2014; 50(6): 587-592.
37. Freedman L. Quantitative science methods for biomarker
validation in chemoprevention trials. Cancer
Biomark. 2007; 3(3): 135-140.
38. Maiti GP, Mondal P, Mukherjee N, Ghosh A, Ghosh
S, Dey S, et al. Overexpression of EGFR in head
and neck squamous cell carcinoma is associated with
inactivation of SH3GL2 and CDC25A genes. PLoS
One. 2013; 8(5): e63440.
39. de Vos L, Gevensleben H, Schröck A, Franzen A,
Kristiansen G, Bootz F, et al. Comparison of quantification
algorithms for circulating cell-free DNA
methylation biomarkers in blood plasma from cancer
patients. Clin Epigenet. 2017; 9: 125.
40. Widschwendter M, Apostolidou S, Raum E, Rothenbacher
D, Fiegl H, Menon U, et al. Epigenotyping
in peripheral blood cell DNA and breast cancer risk:
A proof of principle study. PLoS One. 2008; 3(7):
e2656.
41. Pedersen KS, Bamlet WR, Oberg AL, de Andrade
M, Matsumoto ME, Tang H, et al. Leukocyte DNA
meth-ylation signature differentiates pancreatic cancer
patients from healthy controls. PLoS One. 2011;
6(3): 18223.
42. Marsit CJ, Koestler DC, Christensen BC, Karagas
MR, Houseman EA, Kelsey KT. DNA methylation
array analysis identifies profiles of blood-derived
DNA methylation associated with bladder cancer. J
Clin Oncol. 2011; 29(9): 1133-1139.
43. Pulling LC, Divine KK, Klinge DM, Gilliland FD,
Kang T, Schwartz AG, et al. Promoter hypermethylation
of the O6-methylguanine-DNA methyltransferase
gene: more common in lung adenocarcinomas from
never-smokers than smokers and associated with tumor
progression. Cancer Res. 2003; 63(16): 4842-4848.
44. Liu Y, Lan Q, Siegfried JM, Luketich JD, Keohavong
P. Aberrant promoter methylation of p16 and MGMT
genes in lung tumors from smoking and never-smoking
lung cancer patients. Neoplasia. 2006; 8(1): 46-51.
45. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson
NE, Baylin SB. Methylation of the oestrogen
receptor CpG island links ageing and neoplasia in
human colon. Nat Genet. 1994; 7(4): 536-540.
46. Montero AJ, Diaz-Montero CM, Mao L, Youssef EM,
Estecio M, Shen L, et al. Epigenetic inactivation of
EGFR by CpG island hypermethylation in cancer.
Cancer Biol Ther. 2006; 5(11): 1494-1501.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
